Sp654
DEBATE: STEP DOWN THERAPY STARTING WITH BIOLOGICS
Date
May 19, 2024
Presenter
University of North Carolina School of Medicine
Tracks
Related Products
HISTOLOGIC RESPONSE OR ENDOSCOPIC NORMALIZATION AFTER INTITIAL TREATMENT FOR EOSINOPHILIC ESOPHAGITIS IN CHILDREN LEADS TO LESS FIBROSTENOSIS OVER LONG-TERM FOLLOW-UP
BACKGROUND: Untreated eosinophilic esophagitis (EoE) can result in development of fibrostenosis over time, but there are few data on whether successful treatment in childhood decreases this risk as children with EoE transition to adulthood…
FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
WEIGHT GAIN IS ASSOCIATED WITH DECREASED TREATMENT RESPONSE TO DIET THERAPY IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Dietary therapy is an effective treatment for eosinophilic esophagitis (EoE), however, the influence of body mass index (BMI) on treatment response is unclear…
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
